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Growth differentiation factor 15 (GDF15), a transforming growth
factor (TGF)-β superfamily member, has been cloned from a placenta
cDNA library as a gene product that has promoted activation of
pro-matrix metalloproteinase (MMP)2 mediated by membrane
type (MT)1-MMP. Expression of MT1-MMP in HEK293T cells caused
cleavage of the GDF15 mature form at N252–M253 to produce a 6-kDa
C-terminal fragment. Treatment of MCF7 cells with GDF15 induced
activation of p53 and enhanced expression of p21, which was
abrogated by MT1-MMP expression. GDF15 mRNA synthesis was
also shown to be induced by treatment of cells with GDF15. Treat-
ment of MCF7 cells with GDF15 caused suppression of cell proliferation.
However, proliferation of MCF7 cells transfected with the MT1-MMP
gene was not affected by GDF15 treatment, but was suppressed
in the presence of the MMP inhibitor BB94. HT1080 cells transfected
with the GDF15 gene, which endogenously express MT1-MMP,
synthesize a high-level GDF15 precursor form and a low-level mature
form, and treatment of cells with BB94 enhanced production of the
GDF15 mature form. Consistent with GDF15 production, HT1080
cells transfected with the GDF15 gene proliferated almost equally
with control cells, and addition of BB94 effectively suppressed growth
of HT1080 cells transfected with the GDF15 gene concomitant with
the accumulation of the GDF15 mature form, but not control cells.
These results suggest that MT1-MMP contributes to tumor cell
proliferation through the cleavage of GDF15, which down-regulates
cell proliferation by inducing activation of p53 and p21 synthesis.
(Cancer Sci 2007; 98: 1330–1335)
MMP is a family of Zn2+-dependent enzymes that areessential for ECM turnover in normal and pathological
conditions.(1–3) To date, at least 28 mammalian MMP have been
identified by cDNA cloning, and they can be subgrouped into
soluble MMP and MT-MMP.(4,5) MMP are overexpressed in various
human malignancies and have been considered to be particularly
important in the malignant behavior of tumor cells.(1,3,5) Thus,
the level of MMP expression correlates with the invasiveness
or malignancy of tumors.(6,7) Among the MMP, MT1-MMP,
MMP-2, MMP-7 and MMP-9 have been reported to be most
closely associated with tumor invasion and metastasis. Although
important in the degradation of the ECM, growing evidence has
implicated MMP in specific processing resulting in activation
or degradation of cell surface receptors and ligands.(8) The Fas
ligand,(9) TNF-α,(10) the ectodomain of fibroblast growth factor
receptor-1,(11) heparin-binding epidermal growth factor,(12) and
IL-8,(13) have been reported to be released or activated by MMP. In
contrast, MMP cleave and inactivate IL-1β,(14) the CC chemokine
MCP-3,(15) the CXC chemokines stromal cell-derived factor-1α
and β,(16,17) and KiSS-1/metastin.(18)
GDF15 is a distant member of the TGF-β cytokine super-
family, along with MIC-1, PTGF-β, PLAB, NAG-1, and PDF.(19)
GDF15 behaves as an anti-tumorigenic and pro-apoptotic protein
in the early stage of tumors.(20)
In the present study, the authors demonstrated for the first
time that MT1-MMP cleaves GDF15 between N252–M253, which
abrogates GDF15-induced suppression of tumor cell growth.
Materials and Methods
Materials. DMEM was obtained from Sigma (St Louis, MO,
USA). Primers were synthesized by Genest (Kyoto, Japan). A
human placenta cDNA library constructed in a pEAK8 expression
vector was obtained from EdgeBio System (Gaithersburg, MD,
USA). Monoclonal antibodies against the FLAG epitope were
purchased from Sigma. A monoclonal antibody against MT1-
MMP hemopexin domain (113-5B7), recombinant TIMP-1 and
TIMP-2 proteins were gifts from Daiichi Fine Chemical Co.
Ltd. (Takaoka, Japan). A monoclonal biotinylated-antibody
against human GDF15 and recombinant human GDF protein
were purchased from R&D Systems, Inc. (Minneapolis, MN,
USA). Rabbit antibodies against p21 and phosphorylated p53
were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA) and Cell Signaling Technology (Denvers, MA, USA),
respectively. Monoclonal antibodies against p53 and α-tubulin
were from Calbiochem/EMD Biosciences, Inc. (San Diego, CA,
USA) and Sigma, respectively.
Cell culture. Human embryonic kidney HEK293T cells and
fibrosarcoma HT1080 cells were obtained from ATCC (Manassas,
VA, USA) and cultured in DMEM supplemented with 5% FCS.
Human breast cancer MCF-7 cells were obtained from ATCC
and cultured in DMEM supplemented with 10% FCS.
Preparation of MMP-2 sample. HEK293T cells cultured in 10-cm
diameter dishes were transfected with 10 µg expression plasmid
for pro-MMP-2 using a calcium-phosphate method. Culture
medium was replaced with serum-free DMEM at 48 h after
transfection. The culture supernatant was harvested after 24 h
and used as a pro-MMP-2 sample.
Expression cloning. Expression cloning to identify candidate
genes whose products interact with MT1-MMP was carried out
using the modified method of Miyamori et al.(21) In brief,
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plasmid DNA from placenta cDNA library aliquots (100 ng)
was co-transfected with an MT1-MMP plasmid (30 ng) into
HEK293T cells cultured in a 96-well microplate. At 48 h post-
transfection, cells were incubated with 10-fold-diluted pro-
MMP-2 samples for 1 h, which were then subjected to gelatin
zymography. A pool of cDNA, transfection of which promoted
pro-MMP2 processing, was used to transform Escherichia coli.
A plasmid DNA from an individual bacterial colony, expression
of which promoted activation of pro-MMP2 by MT1-MMP,
was selected and the nucleotide sequence was determined as
described previously.(21)
Construction of expression plasmids. The expression plasmid for
MT1-MMP tagged with the FLAG epitope adjacent to the
furin cleavage site (MT1-FLAG) was constructed as described
previously.(21) The expression plasmid for GDF15 tagged
with the FLAG epitope at the C-terminus (GDF15-FLAG) was
constructed as follows. A GDF15 cDNA fragment containing
XbaI restriction sites in place of the stop codon was generated
by PCR using GDF15 cDNA in a pEAK8 plasmid as a template
and PCR primers of pEAK8 forward primer (TTCATTCTCA-
AGCCTCAGACAGTGG) and flanking reverse primer with an
extra XbaI site (underlined) starting at nucleotide 949 (TTTC-
TAGATATGCAGTGGCAGTCTT) of the GDF15 gene (GenBank
accession no. NM_004864.1). An amplified fragment was digested
with EcoRI and XbaI, and inserted into the EcoRI and XbaI
sites of the pEAK8-FLAG vector as described previously.(21)
Western blotting. Cell lysates or proteins precipitated from
conditioned medium with 10% TCA were analyzed using
western blotting with the indicated antibodies. Goat anti-mouse
or anti-rabbit IgG antibodies conjugated with Alexa Fluor 680
(Molecular Probes Inc., Eugene, OR, USA) were used as a
second antibody. The signal was monitored using a LI-COR
Odyssey IR imaging system (Lincoln, NE, USA). To detect
GDF15, conditioned medium samples were separated using
4%/10%/16% Tris-Tricine SDS-PAGE.(22)
Cell surface biotinylation. Expression plasmids for MT1-FLAG
and GDF15 were cotransfected into HEK293T cells. At 48 h
post-transfection, cell-surface biotinylation and immunopreci-
pitation were performed as described previously.(23) The
immunoprecipitated materials were separated using 15% SDS-
PAGE, then blotted and detected with IRDyeTM800-conjugated
streptavidin.
Determination of the cleavage site of the GDF15 protein.
Expression plasmids for GDF15-FLAG (25 µg) and MT1-MMP
(75 µg) were cotransfected into HEK293T cells cultured in 10
dishes of 10-cm diameter. Culture medium was replaced at
48 h after transfection with serum-free Opti-MEM (Invitrogen,
Carlsbad, CA, USA), and cells were incubated for a further
24 h. Fragments of GDF15-FLAG in the culture supernatant
were purified using a FLAG-M2 antibody bead column,
separated by Tris-Tricine SDS-PAGE, and blotted onto PVDF
membranes. The N-terminal amino acid sequence of a 6-kDa
fragment was determined as described previously.(8)
Real-time PCR assay. A total RNA was isolated as described
previously.(6) cDNA was synthesized using a QuantiTect Reverse
Transfection Kit (Qiagen Inc., Valencia, CA, USA). Real-time
PCR analysis was performed using SYBR Green Realtime PCR
master mix (Toyobo Co., Ltd, Osaka, Japan). The GDF15 mRNA
level was examined using forward primer (TTAGCCAAA-
GACTGCCACTG) starting at nucleotide 926 and reverse primer
(GAATCGGGTGTCTCAGGAAC) starting at nucleotide 1049
of the GDF15 gene (GenBank accession no. NM_004864.1).
Hs_GAPDH_1_SG QuantiTect Primer (Qiagen) was used to
monitor the amplification of GAPDH gene transcript as a control.
GDF15-stable transfectant. HT1080 cells were transfected
with the expression plasmid for GDF15-FLAG, selected
under 0.5 µg/mL puromycin, and single clones were isolated as
described previously.(8)
Cell proliferation assay. MCF7 cells or HT1080 cells (1.0 × 103
cell/well) in 200 µL of culture medium were plated into 96-well
plates. A GDF15 sample of 50 µL was added to the culture with
or without BB94 at 24 h, and cells were incubated for a further
24 h. Cell proliferation was assayed using a Cell Counting
Kit-8 according to the manufacturer’s instructions (Dojindo
Laboratories, Kumamoto, Japan). Statistical analysis was carried
out using a one-tailed t-test.
Results
Expression cloning. Aliquots of plasmid DNA from the human
placenta cDNA library were cotransfected with MT1-MMP
cDNA into 293T cells, and cells were incubated with pro-MMP-2.
Then, cell lysates were analyzed using gelatin zymography
(Fig. 1). Transfection of one pool of cDNA partially stimulated
processing of MMP-2 to the 62-kDa active form. One clone of
21 clones isolated from this cDNA pool by a second screening
stimulated pro-MMP-2 activation when co-transfected with MT1-
MMP cDNA. The size of the cDNA fragment in this plasmid
was approximately 1.2 kbp. Homology search analysis of its
nucleotide sequence revealed that this cDNA encodes GDF15
(GenBankTM accession no., BC008962.2), which has many
synonyms, including MIC-1, PTGF-β, PLAB, NAG-1, and PDF.(20)
GDF15 stabilizes cell-surface MT1-MMP. To explore the mech-
anism of GDF15-induced stimulation of pro-MMP-2 activation by
MT1-MMP, the effect of GDF15 expression on the MT1-MMP
protein level was examined by comparing with that of TIMP-2
(Fig. 2a). Co-expression of TIMP-2 enhanced the expression of
the MT1-MMP active form by 67-fold, as detected using FLAG
M1 antibody, which selectively detects the MT1-MMP active
form. TIMP-2 expression dramatically reduced the level of
the 43-kDa fragment as detected using the anti-MT1-MMP
antibody, which is the auto-degradation product of MT1-
MMP. Co-expression of GDF15 did not significantly affect the
expression of the latent form and the 43-kDa fragment of MT1-
MMP as detected using the anti-MT1-MMP and anti-FLAG M2
antibodies; however, the level of the MT1-MMP active form
was enhanced by seven-fold as detected by the FLAG M1
Fig. 1. Expression cloning. In the first screening, plasmid DNA aliquots
from the human placenta cDNA library were co-transfected with
membrane type (MT)1-matrix metalloproteinase (MMP) into HEK293T
cells cultured in 96-well microplates. At 48 h post-transfection, cells
were incubated with a pro-MMP-2 sample for 1 h, and cell lysates from
each well were subjected to gelatin zymography as described under
Materials and Methods. Partial results of gelatin zymography are
shown. Note that pro-MMP-2 activation to generate the 62-kDa active
form was stimulated in lane 8 (upper panel). In the second screening,
single clones of plasmid DNA were examined as described above. Note
that pro-MMP-2 activation was enhanced in lane 10 (lower panel).
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antibody. These results indicate that co-expression of GDF15
did not affect significantly the expression of the overall MT1-
MMP protein level, but enhanced the level of the MT1-MMP
active form.
To confirm the enhanced expression of the MT1-MMP active
form by GDF15 that appears on the cell surface, the cell-surface
MT1-MMP level was examined by cell-surface biotinylation
followed by immunoprecipitation using FLAG M2 antibody
beads (Fig. 2b). Consistent with the results of western blotting,
the cell-surface MT1-MMP active form level was elevated
by GDF15 expression. Moreover, a 12.5-kDa species was co-
precipitated with MT1-MMP, which is expected to be a mature
form of GDF15. Immunoprecipitation from the lysates of cells
co-transfected with MT1-MMP and GDF15 demonstrated that
the GDF15 mature form (12.5 kDa) was preferentially co-
precipitated with the active form of MT1-MMP, and a minor
part of the GDF15 precursor form (35 kDa) was also co-precipitated
(Fig. 2c). These results suggest that GDF15 stabilizes the MT1-
MMP active form by making a complex with it, which in turn
enhances MT1-MMP-mediated pro-MMP-2 activation.
MT1-MMP cleaves GDF15. Complex formation between the
MT1-MMP active form and the GDF15 mature form led us to
examine whether GDF15 serves as a substrate for MT1-MMP.
An expression plasmid for GDF15 was co-transfected with
the MT1-MMP plasmid, and GDF15 secreted into the culture
medium was examined using western blotting (Fig. 3a).
Transfection of the GDF15 plasmid alone produced a 35-kDa
precursor form and a 12.5-kDa mature form. Co-expression of
MT1-MMP with GDF15 caused a drastic loss in production of
the mature form, and addition of BB94 recovered mature form
production. These results suggest that the GDF15 mature form
serves as a substrate for MT1-MMP. To confirm the cleavage
of GDF15 by MT1-MMP, an expression plasmid for GDF15-
FLAG was co-transfected with the MT1-MMP plasmid.
Secreted GDF15 was separated on Tris-Tricine SDS-PAGE to
detect the small cleavage fragment, and analyzed using an
anti-FLAG M2 antibody (Fig. 3b). Co-expression of MT1-MMP
with GDF15-FLAG reduced production of the GDF15-FLAG
mature form, and a 6-kDa fragment was detected. The addition
of BB94 inhibited conversion of the GDF15 mature form to
the 6-kDa fragment. The addition of recombinant TIMP-2
but not TIMP-1 suppressed conversion from the 12.5-kDa
to the 6.0-kDa fragment by the cells expressing MT1-MMP.
Selective inhibition by TIMP-2 suggests that MT1-MMP is
involved in conversion from the GDF15 mature form to the
6.0-kDa fragment. The cleavage product of GDF15-FLAG
collected on the FLAG M2 antibody beads column was tested
with a peptide sequencer. The N-terminal sequence of the 6-kDa
fragment was MHAQI, indicating that MT1-MMP cleaves the
N252–M253 peptide bond of GDF15.
Effect of MT1-MMP expression on GDF15-induced p53
phosphorylation and p21 expression. GDF15 was reported to induce
cell growth arrest in MCF-7 breast cancer cells.(24) GDF15 was
added to the culture of MCF7 cells, and p53 phosphorylation
at ser15 and p21 expression in these cells was examined
(Fig. 4). The addition of recombinant GDF15 to the mock-
transfected cells induced p53 phosphorylation and p21
expression at 3 h, which continued until 9 h. GDF15 was
equally effective to the cells transfected with the MT1-MMP
gene at 3 h after the addition of GDF15; however, the effect of
 
Fig. 2. Stabilization of cell-surface membrane
type (MT)1-matrix metalloproteinase (MMP) by
growth differentiation factor 15 (GDF15). MT1-
FLAG or a control plasmid (200 ng) was co-
transfected into HEK293T cells cultured in 12-well
microplates with a control (–), GDF15 or TIMP-2
(400 ng) plasmid, and cells were incubated for
48 h. (a) cell lysates were examined for total
MT1-FLAG expression using the anti-MT1-MMP
monoclonal antibody 113-5B7 (upper panel),
FLAG M2 antibody (middle panel), and for the
MT1-FLAG active form using the FLAG M1
antibody (lower panel). (b) transfected cells were
labeled with biotin, and immunoprecipitation
was performed using anti-FLAG M2 beads as
described in Materials and Methods. Precipitated
materials were blotted with IRDyeTM800-conjugated
streptavidin. Note that a 12.5-kDa material was
co-precipitated with MT1-FLAG from cells cotran-
sfected with MT1-FLAG and GDF15 plasmids. (c)
MT1-FLAG was immunoprecipitated from cells
transfected with the indicated plasmid using anti-
FLAG M2 antibody beads, and co-precipitated
GDF15 was detected using western blotting with
an anti-GDF15 antibody (left panel). Aliquots of
total lysates from transfected cells were examined
for GDF15 expression using western blotting
with the anti-GDF15 antibody (right panel).
Note that a 12.5-kDa GDF15 mature form was
predominantly co-precipitated with MT1-FLAG.
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GDF15 was lost in MT1-MMP-transfected cells at 9 h.
Treatment of MT1-MMP-transfected cells with BB94 restored
induction of p53 phosphorylation and p21 expression at 9 h
after the addition of GDF15. The concentration of GDF15
added to the culture was not significantly altered by the
incubation with MT1-MMP-expressing cells for 3 h, but was
reduced by the incubation with MT1-MMP-expressing cells for
9 h. Addition of BB94 to the culture of MT1-MMP-expressing
cells suppressed the reduction of GDF15 concentration. The
expression level of MT1-MMP was constant at 3 h and 9 h after
addition of GDF15.
GDF15 induces GDF15 mRNA synthesis. Treatment of MCF7 cells
with GDF15 induced activation of p53. The GDF15 gene has been
reported to be one of the downstream target genes of p53,(25,26)
which led us to examine whether GDF15 mRNA expression is
stimulated by treatment of MCF7 cells with GDF15 (Fig. 5).
Real-time PCR analysis showed that treatment of MCF7 cells with
GDF15 induced expression of GDF15 mRNA, and induction of
GDF15 mRNA expression by GDF15 was quite ineffective in
MT1-MMP-expressing cells compared with that of control cells.
MT1-MMP abrogates GDF15-induced cell-growth suppression. The
effect of GDF15 on the proliferation of MCF7 cells was examined
(Fig. 6a). The addition of GDF15 to the culture induced growth
retardation of MCF7 cells by 34% (P < 0.001). In contrast, the
growth of cells transfected with the MT1-MMP gene was not signi-
ficantly affected by GDF15 treatment, but GDF15 suppressed
proliferation of MT1-MMP-transfected cells by 43% (P < 0.001)
in the presence of BB94. Next, the effect of GDF15 was exam-
ined using HT1080 cells that endogenously express MT1-MMP.
HT1080 cells stably transfected with the GDF15 gene produced
a high level of the GDF15 precursor form, but the level of the
mature form was low (Fig. 6b). ConA treatment, which enhances
the level of MT1-MMP, further reduced the level of the mature
form, and produced a 6-kDa cleavage fragment. The addition
of BB94 to the culture of GDF15-transfected cells induced
accumulation of the GDF15 mature form. Transfection of the
GDF15 gene did not significantly affect the growth of HT1080
cells (Fig. 6c). The addition of BB94 did not affect the pro-
liferation of mock-transfected cells, although it suppressed the
growth of the GDF15-expressing cells by 35% (P < 0.001)
concomitant with accumulation of the GDF15 mature form.
Fig. 3. Cleavage of growth differentiation factor 15 (GDF15) by
membrane type (MT)1-matrix metalloproteinase (MMP). (a) expression
plasmid for GDF15 (300 ng) was co-transfected with control or MT1-
MMP plasmid (600 ng) into HEK293T cells plated in 12-well microplates.
At 24 h, the post-transfection medium was replaced with serum free
Opti-MEM, and cells were incubated for a further 24 h. BB94 (1.0 × 10–7 M)
was included in Opti-MEM in the indicated culture. Conditioned medium
proteins precipitated with 10% trichloroacetic acid were separated on
15% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-
PAGE) and blotted using anti-GDF15 antibody as described in Materials
and Methods. (b) Expression plasmid for GDF15-FLAG was co-transfected
with control or the MT1-MMP plasmid, and BB94 (1.0 × 10–7 M), recombinant
TIMP-1 or TIMP-2 protein (2.0 µg/mL) was included in the indicated culture
as described above. The conditioned medium proteins were separated
on Tris-Tricine SDS-PAGE and blotted using the FLAG M2 antibody.
Fig. 4. Effect of membrane type (MT)1-matrix
metalloproteinase (MMP) expression on growth
differentiation factor 15 (GDF15)-induced p53
phosphorylation and p21 synthesis. MCF-7 cells in
12-well plates were transfected with control or
an MT1-MMP plasmid (1 µg), and were incubated
with a recombinant GDF15 sample (25 ng in 1 mL
culture) for 3 h or 9 h in the presence or absence
of BB94. Cell lysates were analyzed using western
blotting for the levels of phosphorylated p53
(panel p-p53), total p53 protein (panel p53), p21
protein (panel p21), tubulin protein (panel Tubulin)
and MT1-MMP protein (panel MT1-MMP). GDF15
in the supernatant was also examined using
western blotting (panel GDF15).
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Discussion
Previously, the authors have identified KiSS-1/metastin,
syndecan-1, lumican and APP using the expression cloning strategy
as molecules that serve as substrates for MT1-MMP.(8,18,23,27) In
the present study, it was found that expression of the GDF15
gene stimulated activation of pro-MMP-2 mediated by MT1-MMP
in HEK293T cells. MT1-MMP was shown to form a stable
complex with the GDF15 mature form, resulting in stabilization
of MT1-MMP on the cell surface. This may account for the
stimulatory effect of GDF15 on pro-MMP-2 activation mediated
by MT1-MMP. Previously, the authors identified syndecan-1
and APP as substrates, expression of which stimulated MT1-
MMP-mediated pro-MMP-2 processing. Here, it was also shown
that GDF15 is cleaved at the N252–M253 peptide bond by MT1-
MMP. Because auto-degradation is one of the most common
regulatory steps in MT1-MMP activity, complex formation with
a substrate may interfere with auto-degradation and consequently
augment the activity against favorable substrate pro-MMP-2.
GDF15 is a secretory protein sharing 25% overall sequence
identity with TGF-β superfamily members, but has their main
characters as a signal peptide, a consensus RXXRA/S cleavage
signal for processing to mature form, and seven conserved
cysteine residues in the carboxyl terminal.(28)
GDF15 has been reported to induce cell growth arrest or
apoptosis in MCF-7 breast cancer cells,(24) PC-3 human prostate
carcinoma and xenografted tumors,(29) as well as Du-145 prostate
carcinoma through the TGF-β signaling pathway.(28,30) It has also
mediated TPA-induced apoptosis in LNCaP prostate cancer
cells.(31) Treatment of HEK293 cells with TGF-α1 was reported
Fig. 6. Effect of membrane type (MT)1-matrix
metalloproteinase (MMP) expression on growth
differentiation factor 15 (GDF15)-induced cell-
growth suppression. (a) control or a recombinant
GDF15 (25 ng) was added to the 1-mL culture of
MCF7 cells transfected with a control plasmid or
MT1-MMP plasmid with or without BB94 and the
cell number was compared after 24 h as described
in Materials and Methods. The highest cell
number was arbitrarily set to 100%, and the
numbers of other cells were adjusted accordingly.
Bars indicate mean value. *P < 0.001. (b) HT1080
cells stably transfected with the GDF15-FLAG
plasmid were incubated for 24 h in the presence
or absence of BB94 or Concanavalin A (10 µg/mL).
Conditioned medium proteins were separated on
Tris-Tricine sodium dodecyl sulfate–polyacrylamide
gel electrophoresis and blotted using the FLAG
M2 antibody. Note that the level of GDF15 mature
form (12.5-kDa) increased by BB94 treatment.
(c) HT1080 cells stably transfected with control
plasmid or GDF15-FLAG plasmid were cultured in
the presence or absence of BB94 for 24 h, and the
cell number was compared as described above.
*P < 0.001.
Fig. 5. Growth differentiation factor 15 (GDF15)-induced GDF15 mRNA
synthesis. MCF-7 cells in 35-mm diameter dishes were transfected with
control or an membrane type (MT)1-matrix metalloproteinase (MMP)
plasmid (2 µg), and were incubated with or without a recombinant
GDF15 protein (25 ng/mL) for 9 h. A total mRNA was extracted, and
was subjected to real-time polymerase chain reaction assay to compare
the GDF15 mRNA level as described in Materials and Methods. The
highest mRNA level was arbitrarily set to 100%, and the mRNA levels
of other cells were adjusted accordingly.
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to activate p53 by stimulating its phosphorylation at Ser15,
which leads to apoptosis.(32) In the present study, the authors
demonstrated that treatment of MCF7 cells with GDF15
induced phosphorylation of p53 and expression of p21 con-
comitant with cell growth retardation, which are abrogated by
MT1-MMP expression. The biological functions of p53 depend
on its downstream target genes, such as those for growth arrest
that are mediated by its transactivation of p21 for G1 arrest,(33)
and which may be induced in the absence of Smad signaling
on treatment with GDF15.(26) Furthermore, GDF15 is the down-
stream target gene of p53,(25,26) so GDF15 may induce further
GDF15 mRNA synthesis. Indeed, treatment of MCF7 cells with
GDF15 has been shown to induce GDF15 mRNA synthesis con-
comitant with p53 phosphorylation. Here, it was demonstrated
that GDF15 induces phosphorylation of p53 and increases
p21 as markers of cell growth arrest, and also that cleavage of
GDF15 by MT1-MMP abrogates the GDF15-mediated growth
arrest of these cells. Thus, HT1080 cells, which endogenously
express MT1-MMP, are not sensitive to GDF15, while the addition
of BB94 with GDF15 induces effective growth suppression of
HT1080 cells. The authors propose that combined use of an MMP
inhibitor would enhance the potent cytostatic effect of GDF15.
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